一个新型氮杂萘醌类化合物通过诱导细胞凋亡来抑制肿瘤生长

摘要

Natural product menaquinone has been reported to exhibit antitumor activity mediated by inhibiting IDO-1 enzyme,and naphthoquinone compounds like pyranaphthoquinone have attracted extensive research interests since they share the naphthoquinone pharmacophores.In the present study,a novel series of aza-naphthoquinones was synthesized based on 6,7-dichloroquinoline-5,8-dione structure,and their cytotoxicities were screened using lung cancer cells.Among them CY-26-11 was identified as the most potent one.CY-26-11 concentration-dependently induced apoptosis in A549 human lung adenocarcinoma cells,as indicated by annexin-V staining.Further experimental data show that CY-26-11 down-regulated Bcl-2 while up-regulated Bax and Puma protein levels,and activated caspase-3.Finally,CY-26-11 significantly inhibited the growth of Lewis lung carcinoma xenografts in vivo without significant major toxicities.Taken together,our results demonstrate that CY-26-11 exhibited IDO-1-independent anti-tumor effects both in vitro and in vivo,providing a new anti-tumor mechanism for naphthoquinone compounds.%自发现天然产物甲萘醌具有通过抑制IDO-1酶介导的抗肿瘤活性以来,萘醌类化合物茹吡喃萘醌引起了广泛的科研关注.在本研究中,我们基于6,7-二氯喹啉-5,8-二酮合成了一类新型的氮杂萘醌类化合物并进行了细胞毒筛选,发现其中CY-26-11的活性最佳.Annexin-V染色结果显示,CY-26-11浓度依赖地诱导A549人肺腺癌细胞凋亡.进一步的数据显示CY-26-11可下调抗凋亡蛋白Be1-2,上调促凋亡蛋白Bax以及Puma,并激活caspase-3.最后,CY-26-11在小鼠路易斯肺癌皮下移植瘤模型中取得良好的抑瘤效果.总之,我们的实验结果说明CY-26-11具有良好的不依赖于IDO-1活性的体内外抗肿瘤作用,并为萘醌类化合物提供了抗肿瘤新机制.